Isogenica-Phenotypeca SMART Grant Collaboration
Isogenica-Phenotypeca collaboration spear-headed by SMART Grant award
Isogenica are collaborating with Phenotypeca, a biofoundry business who create and own yeast synthetic biology solutions to make any recombinant protein, including biologic drugs.
Phenotypeca’s platform will deploy yeast-display for VHHs to accelerate drug candidate selection, funded by a £405,794 SMART grant award. The aim of the project will be to create a best-in-class system for high-value products, such as Isogenica VHH antibody-based therapeutics, including multi-specific molecules.
Read the full Press Release and find out how this collaboration advances our discovery efforts.
Isogenica specialises in single-domain biotherapeutics (VHH antibodies). In collaboration with biopharmaceutical partners Isogenica has developed a deep pipeline including two clinical assets and numerous partnered discovery and pre-clinical stage programs.
Isogenica’s library is fully synthetic, providing a key advantage that VHH are generated to specific epitopes which are difficult to target using conventional immunisation methods. Isogenica’s library can be displayed in phage or in the company’s proprietary CIS Display technology. Using our proprietary platform and technology, we deliver therapeutic antibodies that meet the highest standards of quality and developability. Isogenica’s team specialise in discovery projects from target QC to Candidate selection.
VHH represent an ideal format for incorporation in CAR-T, T-cell engaging therapeutics, Antibody Radio Conjugates, Antibody Drug Conjugates and bispecific and multispecific formats. These antibodies are developed to a target product profile with carefully designed affinities, valencies and specificities enabling refined tumour cell targeting and modes of action.
Associate Director Marketing
T +44 1799 533 680